This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks With Huge Insider Buying

Amicus Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Another name that insiders find very attractive here is biotechnology and drugs player Amicus Therapeutics (FOLD), which is focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. Insiders are sniffing out some value here, since the stock has dropped over 20% in the last six months.

Amicus Therapeutics has a market cap of $230 million and an enterprise value of $124 million. This stock trades at a reasonable valuation, with a price-to-sales of 9.92 and a price-to-book of 2.85. Its estimated growth rate for this year is 15.6%, and for next year it's pegged at -5.6%. This is a cash-rich company, since the total cash position on its balance sheet is $108.20 million and its total debt is $1.73 million.

>>4 Biotech Stocks Under $10 With Relative Strength

A beneficial owner just bought 2,949,581 shares, or around $18.58 million worth of stock, at $6.30 per share.

From a technical perspective, FOLD is currently trading below its 50-day moving average and just above its 200-day moving average, which is neutral trendwise. This stock has sold off hard over the last few trading sessions, with shares plunging from $6.89 to a recent low of $4.87 a share. That selloff has been accompanied with heavy selling volume, which is bearish technical action. That said, shares of FOLD have so far been defended right near its 200-day moving average of $4.77 a share.

If you're in the bull camp on FOLD, I would look for long-biased trades if this stock can manage to hold a trend above its 200-day at $4.77 a share with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 222,562 shares as bullish. If FOLD can manage to hold a trend above its 200-day, then I would look to add to any positions once it sustains a move or close back above its 50-day at $5.29 a share with heavy volume. If we get that action, then target a pop towards $6 or possibly a bit higher.

On the flipside, I would avoid FOLD or look for short-biased trades if it fails to get back above its 50-day, and then takes out its 200-day at $4.77 a share with heavy volume. If we get that action, then FOLD will likely re-test its June low of $4.25 a share, or possibly even take that level out.

Amicus shows up on a list of 22 Biopharma Stocks With Breakout Potential in 2012.

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,091.63 +5.00 0.03%
S&P 500 1,989.87 +2.86 0.14%
NASDAQ 4,476.9940 +3.2970 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs